Primary Hyperparathyroidism Global Clinical Trials Review, H1, 2018
- GDHC5030CTIDB
- Pages: 47
- May 2018
- Total Views:1139
- Region : Global
- GlobalData
- Market Research Report
Details
Primary Hyperparathyroidism Global Clinical Trials Review, H1, 2018
Summary
GlobalData's clinical trial report, Primary Hyperparathyroidism Global Clinical Trials Review, H1, 2018" provides an overview of Primary Hyperparathyroidism clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Hyperparathyroidism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
GlobalData Clinical Trials Report Coverage 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Primary Hyperparathyroidism Therapeutics Clinical Trials 23
Prominent Drugs 24
Clinical Trial Profile Snapshots 25
Appendix 45
Abbreviations 45
Definitions 45
Research Methodology 46
Secondary Research 46
About GlobalData 47
Contact Us 47
Source 47
List Of Figure
List of Figures
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region (%), 2018* 6
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8
Primary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2018* 9
Primary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 10
Primary Hyperparathyroidism Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 11
Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials, G7 Countries (%), 2018* 12
Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 13
Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 14
Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials, E7 Countries (%), 2018* 15
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase (%), 2018* 16
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 17
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2018* 18
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2018* 19
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 20
Primary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 21
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 22
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 23
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 24
GlobalData Methodology 46
List Of Table
List of Tables
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region, 2018* 6
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8
Primary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2018* 9
Primary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 10
Primary Hyperparathyroidism Therapeutics Clinical Trials, North America, Top Countries, 2018* 11
Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials, G7 Countries (%), 2018* 12
Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 13
Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 14
Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials, E7 Countries (%), 2018* 15
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase, 2018* 16
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 17
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2018* 18
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2018* 19
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 20
Primary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 21
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 22
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 23
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 24
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Primary Hyperparathyroidism Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Primary Hyperparathyroidism, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Amgen Inc
Kirin Holdings Co Ltd
Pfizer Inc
Novo A/S
Metabolic Research Institute Inc
Lupin Ltd
Laboratories Servier
Istituto Auxologico Italiano
Genthon BV
Genepharm SA
Company Profile
Company Profile Title
Primary Hyperparathyroidism Global Clinical Trials Review, H1, 2018
Summary
GlobalData's clinical trial report, Primary Hyperparathyroidism Global Clinical Trials Review, H1, 2018" provides an overview of Primary Hyperparathyroidism clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Hyperparathyroidism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
GlobalData Clinical Trials Report Coverage 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Primary Hyperparathyroidism Therapeutics Clinical Trials 23
Prominent Drugs 24
Clinical Trial Profile Snapshots 25
Appendix 45
Abbreviations 45
Definitions 45
Research Methodology 46
Secondary Research 46
About GlobalData 47
Contact Us 47
Source 47
List Of Figure
List of Figures
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region (%), 2018* 6
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8
Primary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2018* 9
Primary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 10
Primary Hyperparathyroidism Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 11
Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials, G7 Countries (%), 2018* 12
Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 13
Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 14
Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials, E7 Countries (%), 2018* 15
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase (%), 2018* 16
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 17
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2018* 18
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2018* 19
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 20
Primary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 21
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 22
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 23
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 24
GlobalData Methodology 46
List Of Table
List of Tables
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region, 2018* 6
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8
Primary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2018* 9
Primary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 10
Primary Hyperparathyroidism Therapeutics Clinical Trials, North America, Top Countries, 2018* 11
Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials, G7 Countries (%), 2018* 12
Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 13
Primary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 14
Proportion of Primary Hyperparathyroidism to Hormonal Disorders Clinical Trials, E7 Countries (%), 2018* 15
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase, 2018* 16
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 17
Primary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2018* 18
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2018* 19
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 20
Primary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 21
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 22
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 23
Primary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 24
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Primary Hyperparathyroidism Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Primary Hyperparathyroidism, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Amgen Inc
Kirin Holdings Co Ltd
Pfizer Inc
Novo A/S
Metabolic Research Institute Inc
Lupin Ltd
Laboratories Servier
Istituto Auxologico Italiano
Genthon BV
Genepharm SA
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020